397 related articles for article (PubMed ID: 23246812)
41. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells.
Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y
Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262
[TBL] [Abstract][Full Text] [Related]
42. TP53 mutations in familial breast cancer: functional aspects.
Gasco M; Yulug IG; Crook T
Hum Mutat; 2003 Mar; 21(3):301-6. PubMed ID: 12619116
[TBL] [Abstract][Full Text] [Related]
43. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
44. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.
Jackson JG; Pant V; Li Q; Chang LL; Quintás-Cardama A; Garza D; Tavana O; Yang P; Manshouri T; Li Y; El-Naggar AK; Lozano G
Cancer Cell; 2012 Jun; 21(6):793-806. PubMed ID: 22698404
[TBL] [Abstract][Full Text] [Related]
45. BRD7 is a candidate tumour suppressor gene required for p53 function.
Drost J; Mantovani F; Tocco F; Elkon R; Comel A; Holstege H; Kerkhoven R; Jonkers J; Voorhoeve PM; Agami R; Del Sal G
Nat Cell Biol; 2010 Apr; 12(4):380-9. PubMed ID: 20228809
[TBL] [Abstract][Full Text] [Related]
46. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer.
Végran F; Boidot R; Oudin C; Defrain C; Rebucci M; Lizard-Nacol S
Oncogene; 2007 Jan; 26(2):290-7. PubMed ID: 16847456
[TBL] [Abstract][Full Text] [Related]
47. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors.
Levy CB; Stumbo AC; Ano Bom AP; Portari EA; Cordeiro Y; Silva JL; De Moura-Gallo CV
Int J Biochem Cell Biol; 2011 Jan; 43(1):60-4. PubMed ID: 21056685
[TBL] [Abstract][Full Text] [Related]
48. Cross-platform meta-analysis of multiple gene expression profiles identifies novel expression signatures in acquired anthracycline-resistant breast cancer.
Lee YS; Ryu SW; Bae SJ; Park TH; Kwon K; Noh YH; Kim SY
Oncol Rep; 2015 Apr; 33(4):1985-93. PubMed ID: 25695524
[TBL] [Abstract][Full Text] [Related]
49. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
[TBL] [Abstract][Full Text] [Related]
50. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.
Benor G; Fuks G; Chin SF; Rueda OM; Mukherjee S; Arandkar S; Aylon Y; Caldas C; Domany E; Oren M
Mol Oncol; 2020 Aug; 14(8):1640-1652. PubMed ID: 32484602
[TBL] [Abstract][Full Text] [Related]
51. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients.
Dobes P; Podhorec J; Coufal O; Jureckova A; Petrakova K; Vojtesek B; Hrstka R
Oncol Rep; 2014 Oct; 32(4):1695-702. PubMed ID: 25051299
[TBL] [Abstract][Full Text] [Related]
52. Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
Wosikowski K; Regis JT; Robey RW; Alvarez M; Buters JT; Gudas JM; Bates SE
Cell Growth Differ; 1995 Nov; 6(11):1395-403. PubMed ID: 8562478
[TBL] [Abstract][Full Text] [Related]
53. Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation.
Olbryt M; Rusin A; Fokt I; Habryka A; Tudrej P; Student S; Sochanik A; Zieliński R; Priebe W
Invest New Drugs; 2017 Oct; 35(5):545-555. PubMed ID: 28417283
[TBL] [Abstract][Full Text] [Related]
54. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
[TBL] [Abstract][Full Text] [Related]
55. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.
Bertheau P; Plassa F; Espié M; Turpin E; de Roquancourt A; Marty M; Lerebours F; Beuzard Y; Janin A; de Thé H
Lancet; 2002 Sep; 360(9336):852-4. PubMed ID: 12243922
[TBL] [Abstract][Full Text] [Related]
56. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
57. C
Chang WT; Wu CY; Lin YC; Wu MT; Su KL; Yuan SS; Wang HD; Fong Y; Lin YH; Chiu CC
Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31480728
[TBL] [Abstract][Full Text] [Related]
58. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.
Li J; Yang L; Gaur S; Zhang K; Wu X; Yuan YC; Li H; Hu S; Weng Y; Yen Y
Hum Mutat; 2014 May; 35(5):575-84. PubMed ID: 24677579
[TBL] [Abstract][Full Text] [Related]
59. Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53.
Alli E; Yang JM; Hait WN
Oncogene; 2007 Feb; 26(7):1003-12. PubMed ID: 16909102
[TBL] [Abstract][Full Text] [Related]
60. Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.
Jordan JJ; Inga A; Conway K; Edmiston S; Carey LA; Wu L; Resnick MA
Mol Cancer Res; 2010 May; 8(5):701-16. PubMed ID: 20407015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]